title: High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
abstract: Allogeneic stem cell transplantation (SCT) has been shown to be a curative therapy for some patients with non-Hodgkin's lymphoma (NHL). Total-body irradiation and high-dose cyclophosphamide combinations are the most established conditioning regimens used in this setting. We examined the efficacy and toxicity of cyclophosphamide, BCNU, and VP-16 (CBV) as a suitable chemotherapy-only regimen for NHL patients. In total, 18 patients, median age 42 years, with NHL were treated with CBV followed by allotransplant. Patients had received a median of two prior chemotherapy regimens. Median times to neutrophil and platelet recovery were 19 and 15 days, respectively. Interstitial pneumonitis occurred in one patient. There have been four relapses after a median follow-up of 39 months. Overall, there were four deaths, one because of relapse. The 2-year estimates of relapse-free and overall survival are 56 and 76%, respectively. CBV is a safe and an effective alternative to TBI-containing regimens before allogeneic SCT for NHL.
authors.affiliation: Division of Haematology and Oncology, Umass Memorial Healthcare, North Worcester, MA 01655, USA.
authors.forename: H A
authors.initials: HA
authors.lastname: Rossi
authors.forename: P S
authors.initials: PS
authors.lastname: Becker
authors.forename: R V B
authors.initials: RV
authors.lastname: Emmons
authors.forename: P
authors.initials: P
authors.lastname: Westervelt
authors.forename: W
authors.initials: W
authors.lastname: Levy
authors.forename: Q
authors.initials: Q
authors.lastname: Liu
authors.forename: Y
authors.initials: Y
authors.lastname: Clark
authors.forename: K
authors.initials: K
authors.lastname: Ballen
mesh_terms: D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001792:Blood Platelets / Q000166:cytology; D002330:Carmustine / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007239:Infections / Q000401:mortality; D008107:Liver Diseases / Q000401:mortality; D008171:Lung Diseases / Q000401:mortality; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000166:cytology; D012008:Recurrence; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D003520:Cyclophosphamide; D002330:Carmustine